Clinical Trials Using Tamoxifen Citrate

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Tamoxifen Citrate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-21 of 21
  • Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer

    This randomized phase III trial studies how well hormone therapy when given together with or without everolimus work in treating patients with breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.
    Location: 1374 locations

  • Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer

    This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in the breast to surrounding normal tissue (invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast cancer.
    Location: 1415 locations

  • Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

    This randomized phase II / III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen citrate, paclitaxel, pegylated liposomal doxorubicin hydrochloride, or topotecan hydrochloride in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
    Location: 461 locations

  • First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

    This is a Phase 1, first-in-human, open-label, non-randomized, dose escalation, trial to explore the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity signals of MSC2363318A.
    Location: 10 locations

  • Tamoxifen Citrate or Letrozole with or without Palbociclib in Treating Patients with Stage I-III Invasive Breast Cancer before Surgery

    This phase II clinical trial studies how well tamoxifen citrate or letrozole with or without palbociclib work in treating patients with stage I-III invasive breast cancer before surgery. Antihormone therapies, such as tamoxifen citrate and letrozole, may lessen the amount of estrogen made by the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving tamoxifen citrate or letrozole with or without palbociclib may work better in treating patients with stage I-III invasive breast cancer.
    Location: 10 locations

  • Paclitaxel, Trastuzumab, and Pertuzumab before Surgery in Treating Patients with Inflammatory Breast Cancer

    This phase II trial studies how well paclitaxel, trastuzumab, and pertuzumab before surgery work in treating patients with inflammatory breast cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Pertuzumab may also stop the growth of breast cancer by blocking blood flow to the tumor. Giving paclitaxel, trastuzumab, and pertuzumab may work better in treating breast cancer.
    Location: 6 locations

  • Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+ / HER2- High Risk Early Breast Cancer

    This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk breast cancer.
    Location: 2 locations

  • Tamoxifen Citrate or Afimoxifene in Treating Patients with Estrogen Receptor Positive Breast Cancer

    This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells.
    Location: 6 locations

  • Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

    This is a non-randomized, open-label, single-arm, multicenter, phase II study of palbociclib in combination with tamoxifen in women with HR(+) / HER2(-) advanced breast cancer who have not received prior systemic anticancer therapies for their advanced / metastatic disease.
    Location: 2 locations

  • A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

    The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, or LY3023414 plus fulvestrant) for breast cancer that has spread to other parts of the body.
    Location: 2 locations

  • Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer

    This phase II trial studies how well paclitaxel works with carboplatin before surgery in treating Nigerian women with stage IIA-IIIC breast cancer before surgery. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Fulvestrant or Tamoxifen Citrate in Treating Patients with Cyclin D1 and Estrogen Receptor Positive Breast Cancer

    This randomized phase II trial studies how well fulvestrant or tamoxifen citrate work in treating patients with cyclin D1 and estrogen receptor positive breast cancer. Drugs used in chemotherapy, such as fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Tamoxifen citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether fulvestrant or tamoxifen citrate works better in treating patients with breast cancer.
    Location: Icahn School of Medicine at Mount Sinai, New York, New York

  • Fulvestrant and Tamoxifen Citrate in Treating Patients with Estrogen Receptor Positive Metastatic Breast Cancer

    This randomized phase II trial studies how well fulvestrant and tamoxifen citrate work in treating patients with estrogen receptor positive breast cancer that has spread to other parts of the body. Estrogen can cause the growth of breast tumor cells. Hormone therapy using fulvestrant and tamoxifen citrate may fight estrogen receptor positive metastatic breast cancer by blocking the use of estrogen by the tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

    The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
    Location: The University of Arizona Medical Center-University Campus, Tucson, Arizona

  • Tamoxifen Citrate or Aromatase Inhibitor in Treating Elderly Patients with Estrogen Receptor Positive Breast Cancer That Can Be Removed by Surgery

    This phase II trial studies how well tamoxifen citrate or aromatase inhibitor works in treating elderly patients with estrogen receptor positive breast cancer that can be removed by surgery. Hormone therapy using tamoxifen citrate or aromatase inhibitor may fight estrogen receptor positive breast cancer by lowering the amount of estrogen the body makes and by blocking the use of estrogen by the tumor cells.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Pembrolizumab, Tamoxifen Citrate, and Vorinostat in Treating Patients with Hormone Receptor Positive Stage IV Breast Cancer

    This randomized phase II trial studies the side effects of pembrolizumab, tamoxifen citrate, and vorinostat and how well they work in treating patients with hormone receptor positive stage IV breast cancer. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Estrogen can cause the growth of breast cancer cells. Antihormone therapy, such as tamoxifen citrate, may block the use of estrogen by the tumor cells. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, tamoxifen citrate, and vorinostat may work better in treating patients with hormone receptor positive stage IV breast cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer

    This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or has spread to other places in the body (metastatic). Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant or tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving palbociclib together with fulvestrant or tamoxifen citrate may work better in treating hormone receptor positive breast cancer.
    Location: 13 locations

  • Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer

    This phase II trial studies how well radium Ra 223 dichloride, hormone therapy, and denosumab work in treating patients with hormone-positive breast cancer that has spread from the primary site to the bones and / or bone marrow (bone-dominant metastatic). Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to bone-dominant metastatic breast cancer and not harm normal cells. Hormones can cause the growth of breast cancer cells. Drugs, such as anastrozole, exemestane, fulvestrant, letrozole, and tamoxifen citrate, may lessen the amount of hormones made by the body. Monoclonal antibodies, such as denosumab, may block tumor growth in different ways by targeting certain cells. Giving radium Ra 223 dichloride, hormone therapy, and denosumab may help to control breast cancer that has spread to the bones and / or bone marrow.
    Location: M D Anderson Cancer Center, Houston, Texas

  • TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer

    This is an open label phase II clinical trial to determine the efficacy, toxicity, and safety of TAK-228 plus tamoxifen in patients with newly diagnosed ER-positive, HER2-negative breast cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Endocrine Therapy in Treating Patients with HER2 Negative, Low Risk Breast Cancer

    This pilot phase IV trial studies how well endocrine therapy works in treating patients with HER2 negative, low risk breast cancer. Estrogen can cause the growth of breast cancer cells. Endocrine therapies such as aromatase inhibitors and selective estrogen receptor modulators may lessen the amount of estrogen made by the body.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+ / HER2- Intermediate Risk Early Breast Cancer

    This is an international, multi-center, randomized, double-blinded, placebo-controlled clinical study evaluating the efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, intermediate risk breast cancer.
    Location: 2 locations